Transatlantic commercial agreement set to increase use of rapid mHealth technology

YORK, U.K. - April 2, 2020 - PRLog -- Under the terms of the agreement, the companies will work together to provide DCN Dx's customers with lateral flow testing solutions that incorporate Abingdon Health's Smartphone AppDx technology.

AppDx is cutting-edge mHealth software that turns a Smartphone into a lateral flow reader. By utilising cameras and connectivity within smartphones, AppDx enables rapid test results to be captured and presented locally to the user or cloud connected to stakeholders directly through a data portal. AppDx's provision of lab-quality results in any location creates flexible testing solutions and allows real-time health monitoring and management.

Chris Yates, CEO, of Abingdon Health:

"We are delighted to partner with DCN Diagnostics. We believe our AppDX technology has an important role to play in the decentralization of rapid testing, and DCN Diagnostics is a great partner to support the roll-out of our recently launched technology.

Brendan O'Farrell, President and Founding Partner of DCN Diagnostics:

Comment and full post can be found here: https://www.abingdonhealth.com/abingdon-health-and-dcn-diagnostics-partner-on-commercialisation-of-appdx-m-health-technology/